Experiments on human breast, colon, melanoma, and glioblastoma reveal that IL‐2 and/or IL‐15 activated NK‐cells could identify solid tumor CSCs by involving the receptor‐dependent mechanism, eventually leading to CSC‐elimination in these tumors.149, 150, 151. The gene discussed is IL2; the disease is glioblastoma.